Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from MaxCyte ( (MXCT) ).
MaxCyte, Inc. has announced a change in major holdings, with BlackRock, Inc. now holding 7.90% of voting rights, up from a previous 7.80%. This adjustment in BlackRock’s stake reflects a slight increase in their influence within the company, potentially impacting MaxCyte’s strategic decisions and signaling confidence from a major institutional investor.
More about MaxCyte
MaxCyte, Inc. operates in the biotechnology industry, focusing on cell engineering and providing cell-based therapies. The company is known for its proprietary cell engineering platform that supports a wide range of applications, including drug discovery and development, biomanufacturing, and cell therapy.
Find detailed analytics on MXCT stock on TipRanks’ Stock Analysis page.